EP Patent

EP0759299B1 — Potentiation of serotonin response

Assigned to Eli Lilly and Co · Expires 2000-04-26 · 26y expired

What this patent protects

The availability of serotonin, norepinephrine and dopamine in the brain is increased by administering a serotonin reuptake inhibitor with a serotonin 1A antagonist and L-tryptophan or 5-hydroxy-L-tryptophan.

USPTO Abstract

The availability of serotonin, norepinephrine and dopamine in the brain is increased by administering a serotonin reuptake inhibitor with a serotonin 1A antagonist and L-tryptophan or 5-hydroxy-L-tryptophan.

Drugs covered by this patent

milnacipran-hydrochloride (MILNACIPRAN HYDROCHLORIDE)

Patent Metadata

Patent number: EP0759299B1
Jurisdiction: EP
Classification: —
Expires: 2000-04-26
Drug substance claim: No
Drug product claim: No
Assignee: Eli Lilly and Co
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.